NZ521476A - Microparticles of glycopyrrolate for the treatment of respiratory diseases - Google Patents
Microparticles of glycopyrrolate for the treatment of respiratory diseasesInfo
- Publication number
- NZ521476A NZ521476A NZ521476A NZ52147601A NZ521476A NZ 521476 A NZ521476 A NZ 521476A NZ 521476 A NZ521476 A NZ 521476A NZ 52147601 A NZ52147601 A NZ 52147601A NZ 521476 A NZ521476 A NZ 521476A
- Authority
- NZ
- New Zealand
- Prior art keywords
- glycopyrrolate
- medicament
- disease
- inhaler
- formulation
- Prior art date
Links
- 239000011859 microparticle Substances 0.000 title claims abstract description 29
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 title claims description 74
- 229940015042 glycopyrrolate Drugs 0.000 title claims description 73
- 238000011282 treatment Methods 0.000 title claims description 21
- 208000023504 respiratory system disease Diseases 0.000 title description 8
- 239000000203 mixture Substances 0.000 claims abstract description 60
- 238000009472 formulation Methods 0.000 claims abstract description 40
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 42
- 239000002245 particle Substances 0.000 claims description 21
- 238000013270 controlled release Methods 0.000 claims description 18
- 230000002209 hydrophobic effect Effects 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000000144 pharmacologic effect Effects 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 229940112141 dry powder inhaler Drugs 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 3
- 230000000954 anitussive effect Effects 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940034982 antineoplastic agent Drugs 0.000 claims description 3
- 239000003434 antitussive agent Substances 0.000 claims description 3
- 229940124584 antitussives Drugs 0.000 claims description 3
- 229960000265 cromoglicic acid Drugs 0.000 claims description 3
- 239000003602 elastase inhibitor Substances 0.000 claims description 3
- 239000003172 expectorant agent Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 150000002617 leukotrienes Chemical class 0.000 claims description 3
- 230000000510 mucolytic effect Effects 0.000 claims description 3
- 229940066491 mucolytics Drugs 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 201000005296 lung carcinoma Diseases 0.000 claims description 2
- 229940124761 MMP inhibitor Drugs 0.000 claims 2
- -1 MMP inhibitors Chemical class 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 2
- 239000010419 fine particle Substances 0.000 abstract description 3
- 230000002685 pulmonary effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 9
- 238000003801 milling Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 239000003149 muscarinic antagonist Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 4
- 230000007883 bronchodilation Effects 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 230000001022 anti-muscarinic effect Effects 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 2
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 2
- 229920000538 Poly[(phenyl isocyanate)-co-formaldehyde] Polymers 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000596 artificial lung surfactant Substances 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940125386 long-acting bronchodilator Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013125 spirometry Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0008660.3A GB0008660D0 (en) | 2000-04-07 | 2000-04-07 | The treatment of respiratory diseases |
| PCT/GB2001/001606 WO2001076575A2 (en) | 2000-04-07 | 2001-04-09 | The treatment of respiratory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ521476A true NZ521476A (en) | 2004-10-29 |
Family
ID=9889490
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ535284A NZ535284A (en) | 2000-04-07 | 2001-04-09 | Microparticles of glycopyrrolate for the treatment of respiratory diseases |
| NZ521476A NZ521476A (en) | 2000-04-07 | 2001-04-09 | Microparticles of glycopyrrolate for the treatment of respiratory diseases |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ535284A NZ535284A (en) | 2000-04-07 | 2001-04-09 | Microparticles of glycopyrrolate for the treatment of respiratory diseases |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US7229607B2 (enExample) |
| EP (3) | EP1267866B2 (enExample) |
| JP (1) | JP5042426B2 (enExample) |
| CN (3) | CN1720995A (enExample) |
| AT (1) | ATE330585T2 (enExample) |
| AU (2) | AU2004242450B2 (enExample) |
| BE (1) | BE2013C023I2 (enExample) |
| BR (1) | BR0109875A (enExample) |
| CA (1) | CA2405705C (enExample) |
| CY (1) | CY1105120T1 (enExample) |
| DE (1) | DE60120936T3 (enExample) |
| DK (1) | DK1267866T4 (enExample) |
| ES (2) | ES2266242T5 (enExample) |
| GB (1) | GB0008660D0 (enExample) |
| HK (1) | HK1050846B (enExample) |
| HU (2) | HU230958B1 (enExample) |
| IL (2) | IL151791A0 (enExample) |
| LU (2) | LU92166I2 (enExample) |
| MX (1) | MXPA02009718A (enExample) |
| NO (3) | NO336142B1 (enExample) |
| NZ (2) | NZ535284A (enExample) |
| PL (1) | PL364024A1 (enExample) |
| PT (1) | PT1267866E (enExample) |
| WO (1) | WO2001076575A2 (enExample) |
| ZA (1) | ZA200207420B (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| EP2168571B1 (en) | 2000-11-30 | 2018-08-22 | Vectura Limited | Particles for use in a Pharmaceutical Composition |
| EP2283818B1 (en) | 2000-11-30 | 2017-08-02 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| US20050130990A1 (en) * | 2001-03-23 | 2005-06-16 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| CA2341952A1 (en) | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| CA2447618A1 (en) | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | A composition for regenerative treatment of cartilage disease |
| WO2002094321A1 (en) | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | Compositions for promoting healing of bone fracture |
| LT3494995T (lt) * | 2002-03-01 | 2020-04-10 | Chiesi Farmaceutici S.P.A. | Ypatingai smulki formoterolio kompozicija |
| US8557804B2 (en) | 2002-03-25 | 2013-10-15 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| US8039459B2 (en) | 2004-07-15 | 2011-10-18 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| EP2287326A1 (en) * | 2003-08-08 | 2011-02-23 | Arriva Pharmaceuticals, Inc. | Methods of protein production in yeast |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| ATE530165T1 (de) * | 2003-11-14 | 2011-11-15 | Baxter Int | Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen |
| NZ548300A (en) | 2004-02-06 | 2010-04-30 | Meda Pharma Gmbh & Co Kg | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD |
| CN100512813C (zh) * | 2004-02-06 | 2009-07-15 | Meda制药有限及两合公司 | 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合 |
| WO2005074983A2 (en) * | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids |
| HRP20080439T3 (hr) * | 2004-02-06 | 2008-10-31 | Meda Pharma Gmbh & Co. Kg | Nova kombinacija antikolinergika i beta mimetika za liječenje respiratornih bolesti |
| JP2007524698A (ja) * | 2004-02-27 | 2007-08-30 | アルタナ ファルマ アクチエンゲゼルシャフト | シクレソニドとグリコピロニウムとの組合せ物 |
| EP1737499A4 (en) * | 2004-03-09 | 2009-07-22 | Arriva Pharmaceuticals Inc | TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER |
| GB0409703D0 (en) | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
| GB0410398D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| JP2008504341A (ja) * | 2004-06-29 | 2008-02-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ステロイドと抗コリン作用剤とを含む吸入用薬剤 |
| EP1616567A1 (en) * | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| EP1789018A1 (en) | 2004-08-27 | 2007-05-30 | The Dow Chemical Company | Enhanced delivery of drug compositions to treat life threatening infections |
| US20070105768A1 (en) * | 2004-11-10 | 2007-05-10 | Rajiv Nayar | Dry recombinant human alpha 1-antitrypsin formulation |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| EP1849830B1 (en) * | 2005-01-28 | 2012-02-29 | Takeda Pharmaceutical Company Limited | Finely divided composition containing poorly water soluble substance |
| HRP20160373T1 (hr) | 2005-03-16 | 2016-05-06 | Meda Pharma Gmbh & Co. Kg | Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava |
| US7915303B2 (en) * | 2005-03-24 | 2011-03-29 | Sosei R&D Ltd. | Glycopyrronium salts and their therapeutic use |
| JP2009519970A (ja) * | 2005-12-15 | 2009-05-21 | アキュスフィア， インコーポレイテッド | 粒子ベースの経口投与用製薬剤形の製造方法 |
| ES2389231T3 (es) * | 2005-12-21 | 2012-10-24 | Meda Pharma Gmbh & Co. Kg | Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias |
| GB2434098A (en) * | 2005-12-23 | 2007-07-18 | Novartis Ag | Process for the preparation of an inhalable dry powder formulation |
| WO2007109142A2 (en) * | 2006-03-17 | 2007-09-27 | Oregon Health & Science University | M3 muscarinic receptor antagonists for treating tumors |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| AU2008334547B2 (en) * | 2007-12-13 | 2011-06-30 | Novartis Ag | Organic compounds |
| JP2011506399A (ja) * | 2007-12-13 | 2011-03-03 | ノバルティス アーゲー | 有機化合物 |
| EP2257172A4 (en) * | 2008-02-26 | 2013-07-03 | Elevation Pharmaceuticals Inc | METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION |
| US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| DK2400950T3 (da) | 2009-02-26 | 2019-07-29 | Glaxo Group Ltd | Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
| PT3111927T (pt) | 2009-05-29 | 2020-03-03 | Pearl Therapeutics Inc | Composições para administração respiratória de agentes ativos e métodos e sistemas associados |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| ES2467928T3 (es) | 2009-12-23 | 2014-06-13 | Chiesi Farmaceutici S.P.A. | Formulación en aerosol para EPOC |
| BR112012015334A2 (pt) | 2009-12-23 | 2016-03-15 | Chiesi Farma Spa | terapia combinada para doença pulmonar obstrutiva crônica |
| WO2011076843A2 (en) | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| GEP20166479B (en) | 2009-12-23 | 2016-05-25 | Chiesi Farma Spa | Aerosol formulation for copd |
| CN107096014B (zh) | 2010-09-29 | 2022-07-15 | 普马特里克斯营业公司 | 吸入用单价金属阳离子干粉剂 |
| JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| SI2739268T1 (sl) | 2011-08-01 | 2019-05-31 | Monash University | Postopek in formulacija za inhaliranje |
| CN104487075A (zh) | 2012-02-29 | 2015-04-01 | 普马特里克斯公司 | 可吸入干粉剂 |
| TR201902687T4 (tr) | 2013-03-15 | 2019-03-21 | Pearl Therapeutics Inc | İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler. |
| WO2014165303A1 (en) | 2013-04-01 | 2014-10-09 | Pulmatrix, Inc. | Tiotropium dry powders |
| US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| US20160317391A1 (en) * | 2013-12-17 | 2016-11-03 | Merck Sharp & Dohme Corp. | Media milling process for the manufacture of active pharmaceutical ingredients in propellants |
| BR112016014583B1 (pt) | 2013-12-30 | 2022-12-20 | Chiesi Farmaceutici S.P.A | Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição |
| RS60299B1 (sr) | 2014-09-09 | 2020-07-31 | Vectura Ltd | Formulacija koja obuhvata glikopirolat, postupak i uređaj |
| RU2699995C2 (ru) * | 2014-09-15 | 2019-09-12 | ВЕРОНА ФАРМА ПиэЛСи | Жидкая ингаляционная композиция, содержащая rpl 554 |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| US20160310410A1 (en) | 2015-04-24 | 2016-10-27 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising arformoterol and glycopyrronium |
| MX389992B (es) * | 2015-06-15 | 2025-03-20 | Qaam Pharmaceuticals Llc | Sales de ácido graso de glicopirronio y métodos para elaborar las mismas |
| US9925168B2 (en) * | 2016-01-22 | 2018-03-27 | Chiesi Farmaceutici S.P.A. | Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation |
| US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| AU2019477296A1 (en) | 2019-12-02 | 2022-04-14 | Chiesi Farmaceutici S.P.A. | Stainles steel can for pressurised metered dose inhalers |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3400197A (en) | 1965-01-26 | 1968-09-03 | Robins Co Inc A H | Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules |
| US5376386A (en) * | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
| US5849263A (en) | 1993-03-30 | 1998-12-15 | Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions containing alkylaryl polyether alcohol polymer |
| TW402506B (en) * | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
| DE4425255A1 (de) * | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
| SA95160463B1 (ar) * | 1994-12-22 | 2005-10-04 | استرا أكتيبولاج | مساحيق للاستنشاق |
| US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| US5690374A (en) * | 1996-04-19 | 1997-11-25 | Nor-Easter Enterprises, Inc. | Shock-absorbing tool handle |
| US6613795B2 (en) | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
| NZ336202A (en) | 1996-11-11 | 2000-10-27 | Christian R Noe | Pure enantiomer aryl-cycloalkyl-hydroxycarboxylic acid esters and use in treating smooth muscle spasms and respiritory diseases |
| ES2236832T3 (es) * | 1997-01-16 | 2005-07-16 | Massachusetts Institute Of Technology | Preparacion de particulas para inhalacion. |
| SE9700133D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| AU718967B2 (en) * | 1997-02-05 | 2000-05-04 | Jagotec Ag | Medical aerosol formulations |
| US6495167B2 (en) * | 1997-03-20 | 2002-12-17 | Schering Corporation | Preparation of powder agglomerates |
| US6585958B1 (en) * | 1998-07-24 | 2003-07-01 | Jago Research Ag | Medicinal aerosol formulations |
| CA2338680C (en) * | 1998-08-04 | 2008-10-14 | Jago Research Ag | Medicinal aerosol formulations |
| HU226164B1 (en) | 1998-11-13 | 2008-05-28 | Jagotec Ag | Use of magnesium stearate in dry powder compositions suitable for inhalation and compositions suitable for inhalation |
| US6406745B1 (en) * | 1999-06-07 | 2002-06-18 | Nanosphere, Inc. | Methods for coating particles and particles produced thereby |
| AU7389300A (en) * | 1999-08-02 | 2001-02-19 | First Horizon Pharmaceutical Corporation | Methods of administration of glycopyrrolate compositions |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| US6758795B2 (en) | 2000-08-22 | 2004-07-06 | Stephen Barber | Adjustable water-fillable exercise weights |
| GB0029903D0 (en) * | 2000-12-07 | 2001-01-24 | Arakis Ltd | Use of anti-muscarinic agents |
| GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0410398D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| TWI509631B (zh) | 2011-02-25 | 2015-11-21 | 漢高智慧財產控股公司 | 用於電子裝置之可燒結銀薄片黏著劑 |
-
2000
- 2000-04-07 GB GBGB0008660.3A patent/GB0008660D0/en not_active Ceased
-
2001
- 2001-04-09 IL IL15179101A patent/IL151791A0/xx unknown
- 2001-04-09 HK HK03101991.4A patent/HK1050846B/en unknown
- 2001-04-09 JP JP2001574093A patent/JP5042426B2/ja not_active Expired - Lifetime
- 2001-04-09 CN CNA200510076362XA patent/CN1720995A/zh active Pending
- 2001-04-09 AT AT01966751T patent/ATE330585T2/de active
- 2001-04-09 DE DE60120936.2T patent/DE60120936T3/de not_active Expired - Lifetime
- 2001-04-09 HU HU0301518A patent/HU230958B1/hu active Protection Beyond IP Right Term
- 2001-04-09 CA CA2405705A patent/CA2405705C/en not_active Expired - Lifetime
- 2001-04-09 NZ NZ535284A patent/NZ535284A/xx not_active IP Right Cessation
- 2001-04-09 WO PCT/GB2001/001606 patent/WO2001076575A2/en not_active Ceased
- 2001-04-09 ES ES01966751.8T patent/ES2266242T5/es not_active Expired - Lifetime
- 2001-04-09 DK DK01966751.8T patent/DK1267866T4/en active
- 2001-04-09 PT PT01966751T patent/PT1267866E/pt unknown
- 2001-04-09 CN CNB018075584A patent/CN1292745C/zh not_active Expired - Lifetime
- 2001-04-09 BR BR0109875-6A patent/BR0109875A/pt not_active Application Discontinuation
- 2001-04-09 ES ES04011047.0T patent/ES2687751T3/es not_active Expired - Lifetime
- 2001-04-09 NZ NZ521476A patent/NZ521476A/en not_active IP Right Cessation
- 2001-04-09 MX MXPA02009718A patent/MXPA02009718A/es active IP Right Grant
- 2001-04-09 EP EP01966751.8A patent/EP1267866B2/en not_active Expired - Lifetime
- 2001-04-09 EP EP10153877A patent/EP2193791A1/en not_active Withdrawn
- 2001-04-09 CN CN2007101471670A patent/CN101181263B/zh not_active Expired - Lifetime
- 2001-04-09 PL PL01364024A patent/PL364024A1/xx not_active Application Discontinuation
- 2001-04-09 EP EP04011047.0A patent/EP1449528B1/en not_active Expired - Lifetime
-
2002
- 2002-09-16 ZA ZA200207420A patent/ZA200207420B/en unknown
- 2002-09-18 IL IL151791A patent/IL151791A/en active IP Right Grant
- 2002-10-01 NO NO20024708A patent/NO336142B1/no not_active IP Right Cessation
- 2002-10-07 US US10/266,717 patent/US7229607B2/en not_active Expired - Lifetime
-
2004
- 2004-08-24 US US10/926,196 patent/US7368104B2/en not_active Expired - Lifetime
- 2004-12-22 AU AU2004242450A patent/AU2004242450B2/en not_active Expired
-
2006
- 2006-07-31 CY CY20061101079T patent/CY1105120T1/el unknown
-
2008
- 2008-03-14 US US12/048,812 patent/US8029768B2/en not_active Expired - Lifetime
-
2010
- 2010-02-23 AU AU2010200660A patent/AU2010200660B2/en active Active
-
2013
- 2013-03-13 LU LU92166C patent/LU92166I2/fr unknown
- 2013-03-26 BE BE2013C023C patent/BE2013C023I2/fr unknown
-
2014
- 2014-03-07 LU LU92393C patent/LU92393I2/xx unknown
-
2015
- 2015-11-25 NO NO2015025C patent/NO2015025I1/no not_active Application Discontinuation
- 2015-11-25 NO NO2015024C patent/NO2015024I1/no not_active IP Right Cessation
-
2019
- 2019-12-23 HU HUS1900056C patent/HUS1900056I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2405705C (en) | The treatment of respiratory diseases | |
| US20070243260A1 (en) | Treatment of Childhood Asthma | |
| US20080020048A1 (en) | Treatment of Respiratory Disease | |
| AU776913C (en) | The treatment of respiratory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 09 APR 2021 BY LEA Effective date: 20140402 |
|
| ASS | Change of ownership |
Owner name: HEPTARES THERAPEUTICS LIMITED, GB Effective date: 20190118 |
|
| EXPY | Patent expired |